Amgen (AMGN): Little Impact Expected From Parsabiv Rejection - Baird
Get instant alerts when news breaks on your stocks. Claim your 2-week free trial to StreetInsider Premium here.
Baird analyst, Brian Skorney, reiterated his Outperform rating on shares of Amgen (NASDAQ: AMGN) after the Parsabiv FDA rejection. Amgen's Parsabiv, a calcimimetic under review by the FDA for secondary hyperthyroidism, received a complete response letter. Amgen has spoken positively about the program in light of Phase 3 results. Despite the surprising decision, the analyst is not currently modeling sales for Parsabiv separate from Sensipar, and expects minimal impact to the stock.
No change to the price target of $157.
Shares of Amgen closed at $170.84 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- UPDATE: Cowen Downgrades Under Armour, Inc. (UA) to Market Perform
- AK Steel (AKS) PT, Estimates Raised at Jefferies
- FBR Capital Remains Bullish Following Select Income REIT's (SIR) 3Q Miss
Create E-mail Alert Related CategoriesAnalyst Comments, Analyst EPS View, FDA
Related EntitiesRobert W Baird
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!